Sudler & Hennessey named global AOR for developmental arthritis med

Share this article:
Sudler & Hennessey (S&H) has been selected by AstraZeneca as the global agency partner of record for the developmental arthritis treatment PN400.

S&H duties will include developing the strategy, pre-launch branding and launch campaign for the drug.

PN400 is an investigational fixed dose combination of naproxen and immediate release esomeprazole under co-development with specialty drugmaker Pozen. PN 400 is currently in phase III development for patients who require chronic non-steroidal anti-inflammation drug (NSAID) treatment for arthritis pain and are at risk for NSAID associated gastric ulcers.

An NDA is targeted for the first half of 2009, according to AstraZeneca and Pozen.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.